pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
13704G | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13704G | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13704G | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13704G | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13704G | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10137M | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10137M | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9103D | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3448L | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3448L | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12329X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12329X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12329X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12329X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12329X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12763R | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
14285W | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
13686H | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13686H | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13686H | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13686H | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13686H | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13299Y | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14093 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
6367D | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6367D | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6367D | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6367D | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
13687J | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13687J | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13687J | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13687J | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10058J | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10058J | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10058J | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10058J | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10058J | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10058J | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12090H | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment in a patient weighing less than 30 kg | 14084 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
14235F | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
14235F | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
14235F | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
14235F | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11202N | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Subsequent continuing treatment | 9156 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12566J | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled pen | rheumatoid arthritis | Balance of supply for Initial treatment, Continuing treatment - subcutaneous form | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3430M | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3430M | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3430M | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3430M | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12349Y | adalimumab | Amgevita | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
12792G | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12796L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |